BJDX vs. NMRD, SINT, OSAP, RSLS, DYNT, MOTS, INVO, QNRX, TNON, and IONM
Should you be buying Bluejay Diagnostics stock or one of its competitors? The main competitors of Bluejay Diagnostics include Nemaura Medical (NMRD), Sintx Technologies (SINT), ProSomnus (OSAP), ReShape Lifesciences (RSLS), Dynatronics (DYNT), Motus GI (MOTS), INVO Bioscience (INVO), Quoin Pharmaceuticals (QNRX), Tenon Medical (TNON), and Assure (IONM). These companies are all part of the "surgical & medical instruments" industry.
Bluejay Diagnostics (NASDAQ:BJDX) and Nemaura Medical (NASDAQ:NMRD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.
18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are held by institutional investors. 17.6% of Bluejay Diagnostics shares are held by insiders. Comparatively, 41.6% of Nemaura Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Bluejay Diagnostics has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.
Nemaura Medical has a consensus target price of $2.50, indicating a potential upside of 5,455.56%. Given Nemaura Medical's stronger consensus rating and higher possible upside, analysts clearly believe Nemaura Medical is more favorable than Bluejay Diagnostics.
Nemaura Medical received 2 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 57.14% of users gave Nemaura Medical an outperform vote.
In the previous week, Bluejay Diagnostics had 2 more articles in the media than Nemaura Medical. MarketBeat recorded 3 mentions for Bluejay Diagnostics and 1 mentions for Nemaura Medical. Bluejay Diagnostics' average media sentiment score of 0.93 beat Nemaura Medical's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.
Nemaura Medical's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.
Bluejay Diagnostics has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Bluejay Diagnostics beats Nemaura Medical on 9 of the 17 factors compared between the two stocks.
Get Bluejay Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BJDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bluejay Diagnostics Competitors List
Related Companies and Tools
